HUP0104619A3 - Use of pde inhibitors in the manufacture of a medicament for the treatment of bladder diseases - Google Patents

Use of pde inhibitors in the manufacture of a medicament for the treatment of bladder diseases

Info

Publication number
HUP0104619A3
HUP0104619A3 HU0104619A HUP0104619A HUP0104619A3 HU P0104619 A3 HUP0104619 A3 HU P0104619A3 HU 0104619 A HU0104619 A HU 0104619A HU P0104619 A HUP0104619 A HU P0104619A HU P0104619 A3 HUP0104619 A3 HU P0104619A3
Authority
HU
Hungary
Prior art keywords
medicament
manufacture
treatment
pde inhibitors
bladder diseases
Prior art date
Application number
HU0104619A
Other languages
English (en)
Original Assignee
Jonas Udo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jonas Udo filed Critical Jonas Udo
Publication of HUP0104619A2 publication Critical patent/HUP0104619A2/hu
Publication of HUP0104619A3 publication Critical patent/HUP0104619A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU0104619A 1995-08-08 1996-08-01 Use of pde inhibitors in the manufacture of a medicament for the treatment of bladder diseases HUP0104619A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19529102A DE19529102A1 (de) 1995-08-08 1995-08-08 Verwendung von PDE-Inhibitoren bei der Behandlung von Harnblasenerkrankungen
PCT/EP1996/003393 WO1997005876A1 (en) 1995-08-08 1996-08-01 Use of pde inhibitors in the manufacture of a medicament for the treatment of bladder diseases

Publications (2)

Publication Number Publication Date
HUP0104619A2 HUP0104619A2 (hu) 2002-04-29
HUP0104619A3 true HUP0104619A3 (en) 2002-06-28

Family

ID=7768971

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0104619A HUP0104619A3 (en) 1995-08-08 1996-08-01 Use of pde inhibitors in the manufacture of a medicament for the treatment of bladder diseases

Country Status (9)

Country Link
EP (1) EP0843553A1 (hu)
JP (1) JP2000501698A (hu)
AU (1) AU6702596A (hu)
CA (1) CA2228314A1 (hu)
DE (1) DE19529102A1 (hu)
EA (1) EA199800192A1 (hu)
HU (1) HUP0104619A3 (hu)
WO (1) WO1997005876A1 (hu)
ZA (1) ZA966698B (hu)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020025969A1 (en) * 1997-07-09 2002-02-28 Wolf-Georg Forssmann Use of phosphordiesterase inhibitors in the treatment of prostatic diseases
US6417208B1 (en) * 1999-02-05 2002-07-09 Albert Einstein College Of Medicine Of Yeshiva University Method of identification of inhibitors of PDE1C
AU7360700A (en) * 1999-09-09 2001-04-10 Androsolutions, Inc. Methods and compositions for preventing and treating urinary tract disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2549480B2 (ja) * 1991-12-10 1996-10-30 ヘキストジャパン株式会社 排尿障害改善剤
DE19501482A1 (de) * 1995-01-19 1996-07-25 Bayer Ag 2,9-disubstituierte Purin-6-one

Also Published As

Publication number Publication date
CA2228314A1 (en) 1997-02-20
DE19529102A1 (de) 1997-02-13
JP2000501698A (ja) 2000-02-15
ZA966698B (en) 1998-02-09
EP0843553A1 (en) 1998-05-27
EA199800192A1 (ru) 1999-06-24
HUP0104619A2 (hu) 2002-04-29
AU6702596A (en) 1997-03-05
WO1997005876A1 (en) 1997-02-20

Similar Documents

Publication Publication Date Title
IL174732A0 (en) Use of crystal modification of a n-phenyl-2-pyrimidineamine derivative in the preparation of a medicament for the treatment of restenosis
HK1009939A1 (en) Medicament for treating cardiac inflammatory diseases
EP1029540A3 (en) Use of droloxifene for the treatment of cardiovascular diseases
IL119894A (en) Use of thiazolidine in the preparation of a medicament for the treatment of osteoporosis
IL106776A0 (en) Use of a kallikrein inhibitor for the production of a pharmaceutical for the prophylaxis and therapy of certain diseases
LT97135A (en) Use of melatonin in the manufacture of a medicament for treating patients suffering from drug addiction
HK1022269A1 (en) Use of 1-hydroxy-2-pyridones in the manufacture of a medicament for treating skin infections
HK1001375A1 (en) Use of acetylsalicylic acid in the manufacture of a drug for the treatment of skin injuries
EP0423943A3 (en) Use of collagenase inhibitors in the treatment of demyelinating diseases, in particular multiple sclerosis
AU1116895A (en) Use of theophylline for the manufacture of a medicament for the treatment of asthma
EP0740936A3 (fr) Utilisation des dérivés du benzopyrane pour l' obtention de compositions pharmaceutiques destinées au traitement des pathologies liées a l'énchangeur Cl-/HCO3-,Na+ indépendant
EP0765661A3 (en) Use of docosahexaenoic acid for the manufacture of a medicament for the treatment of glumerulonephritis
AU3684395A (en) Use of camptothecin or derivatives thereof for the manufacture of a medicament for the treatment of viral diseases
HUP0104619A3 (en) Use of pde inhibitors in the manufacture of a medicament for the treatment of bladder diseases
EP0689839A3 (en) Use of adenosine triphosphatase inhibitors for the manufacture of a medicament for the treatment of beta-amyloid peptide-associated disorders
HUP9801686A3 (en) Use of aminotetralin derivative for producing pharmaceutical for the therapy of cardiovascular diseases
IL115505A (en) Use of inhibitors of cyclooxygenase in the preparation of medicaments for the treatment of neurodegenerative diseases
IL114655A (en) USE OF GnRH ANTAGONIST IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF A GONADAL-STEROID DEPENDENT CONDITION IN A MAMMAL
AU7726796A (en) Use of 3-oxa-d-prostaglandins for the manufacture of a medicament for the treatment of glaucoma
NO990949D0 (no) Anvendelse av PKC-inhibitorer til fremstilling av et medikament for behandling av AIDS
ZA95908B (en) A synergistic formulation for treatment of rheumatic diseases
AU3071999A (en) Use of pkc inhibitors for the manufacture of a medicament for the treatment of autoimmune diseases
AU2462097A (en) The use of a substance p antagonist for the manufacture of medicament for the treatment of ocular pain
EP0878200A4 (en) THERAPEUTIC AGENT FOR OPHTHALMIC DISEASES
HUP0004647A3 (en) Use of glycosaminoglycans for producing pharmaceutical preparations for treating diabetes-associated diseases of the eye